40 Erie Street
Suite 130
Cambridge, MA 02139
United States
857 285 6200
https://www.intelliatx.com
Setor(es): Healthcare
Indústria: Biotechnology
Funcionários Integrais: 526
Nome | Título | Pagar | Exercido | Nascido em |
---|---|---|---|---|
Dr. John M. Leonard M.D. | President, CEO & Director | 1,06M | N/A | 1957 |
Mr. Glenn G. Goddard CPA | Executive VP, CFO & Treasurer | 630,91k | N/A | 1971 |
Dr. Laura Sepp-Lorenzino Ph.D. | Executive VP & Chief Scientific Officer | 670,58k | N/A | 1961 |
Mr. James E. Basta Esq., J.D. | Executive VP, General Counsel & Corporate Secretary | 616,15k | N/A | 1966 |
Dr. David Lebwohl M.D. | Executive VP & Chief Medical Officer | 671,42k | N/A | 1955 |
Mr. Derek Hicks | Executive VP & Chief Business Officer | 823,42k | N/A | 1974 |
Mr. Nessan Bermingham Ph.D. | Founder & Member of Scientific Advisor Board | 1,38M | N/A | 1973 |
Dr. Rachel E. Haurwitz Ph.D. | Co-Founder | N/A | N/A | 1986 |
Dr. Andrew May Ph.D. | Founder and Member of Scientific Advisor Board | N/A | N/A | N/A |
Dr. Jennifer A. Doudna Ph.D. | Founder & Member of Scientific Advisor Board | N/A | N/A | 1964 |
O QualityScore de governança da ISS da Intellia Therapeutics, Inc. a partir de 1 de abril de 2024 é 7. As principais pontuações para Auditoria são: 5; Conselho: 8; Direitos de Acionistas: 8; Compensação: 5.